The effects of cardioselective vasodilating beta-blockers on lipids.
Ideally, an antihypertensive agent should have a neutral effect or, preferably, produce a favorable shift in the serum lipid and lipoprotein profile, which is associated with a decrease in coronary heart disease risk. The thiazides and loop diuretics increase total lipid levels, low-density lipoprotein (LDL) cholesterol, and triglycerides. beta-Blockers without beta 2-agonist properties increase triglycerides and decrease high-density lipoprotein (HDL) cholesterol levels. Calcium antagonists, angiotensin converting enzyme inhibitors, and combined alpha/beta-blockers are generally thought to have little effect on the lipid profile, although some studies have indicated a modest beneficial effect. alpha-Adrenoceptor antagonists are known to reduce LDL cholesterol levels modestly and to increase HDL cholesterol levels. The overall results of the currently available studies with celiprolol, a selective beta 1-antagonist with ancillary beta 2-agonist and vasodilating properties, indicate a favorable effect of the drug on serum lipid and lipoprotein profiles.
Hunninghake
D B
DB
Heart Disease Prevention Clinic, University of Minnesota, Minneapolis 55455.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D017272:Celiprolol; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D006801:Humans; D011412:Propanolamines / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood*; D014665:Vasodilator Agents / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D011412:Propanolamines; D014280:Triglycerides; D014665:Vasodilator Agents; D017272:Celiprolol